Increased serum levels of lipoprotein(a) correlated with the severity of coronary artery disease in patients submitted to angiography;Níveis plasmáticos elevados de lipoproteína(a) correlacionados com a gravidade da doença arterial coronariana em pacientes submetidos à angiografia

Arquivos Brasileiros de Cardiologia

Volumn 87, Issue 3, 2006, Pages

  Lima, Luciana Moreira ^a   Carvalho, Maria Das Graças ^a   Loures Vale, Andréia Assis ^a   Fernandes, Ana Paula ^a   Mota, Ana Paula Lucas ^a   Neto, Cirilo Pereira Da Fonseca ^a   Garcia, José Carlos Faria ^a   Saad, Jamil Abdala ^a   Souza, Marinez De Oliveira ^a,b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b NONE   (Brazil)

Author keywords

Coronary angiography; Coronary artery disease; Lipoprotein(a)

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER; LIPOPROTEIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROMATOSIS; BLOOD SAMPLING; CHEMICAL ANALYSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; BLOOD; CASE CONTROL STUDY; CORONARY ARTERY ATHEROSCLEROSIS; HOSPITALIZATION; MIDDLE AGED; RADIOGRAPHY;

AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; LIPOPROTEIN(A); LIPOPROTEINS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 33750290780     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. American Heart Association (AHA). NCEP Report: Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-39.
2. European Society of Cardiology (ESC). European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur J Card Prev Reh 2003;10(Supl I): S1-78.
3. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions. Circulation 2001;104:1108-13.
4. Sociedade Brasileira de Cardiologia (SBC). III Diretrizes Brasileiras Sobre Dislipidemias e Diretrizes de Prevenção da Aterosclerose. Arq Bras Cardiol 2001;77(Supl III):1-48.
5. Berg K. A new serum type system in man-the Lp system. Acta Pathol Scand 1963;59:382-86.
6. Koschinsky ML. Lipoprotein(a) and the link between atherosclerosis and trombosis. Can J Cardiol 2004;20(Supl B):37B-43B.
7. Hajjar KA, Nachman RL. The role of lipoprotein(a) in atherogenesis and thrombosis. Ann Rev Med 1996;47:423-42.
8. Lauber C, De Bacquer D, De Backer G, et al. Plasma lipoprotein(a) values and severity of coronary artery disease in a large population of patients undergoing coronary angiography. Clin Chem 1992;38:2261-6.
9. Pati U, Pati N. Lipoprotein(a), atherosclerosis, and apolipoprotein(a) gene polymorphism. Mol Gen Met 2000;71:87-92.
10. Genest J, Jenner JL, McNamara JR, et al. Prevalence of lipoprotein(a) [Lp(a)] excess in coronary artery disease. Am J Cardiol 1991;67:1039-45.
11. Anglés-Cano E, Penã-Díaz A, Loyau S. Inhibition of fibrinolysis by lipoprotein(a). Ann N Y Acad Sci 2001;936:261-75.
12. Hancock MA, Boffa MB, Marcovina SM, et al. Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J Biol Chem 2003;278:23260-9.
13. Peña-Díaz A, Izaguirre-Avila R, Anglés-Cano E. Lipoprotein Lp(a) and atherothrombotic disease. Arch Med Res 2000;31:353-59.
14. Frohlich J, Dobíasova M, Adler L, et al. Gender differences in plasma levels of lipoprotein(a) in patients with angiographically proven coronary artery disease. Physiol Res 2004;53:481-6.
15. Fujino A, Watanabe T, Kunii H, et al. Lipoprotein(a) is a potential coronary risk factor. Jpn Circ J 2000;64:51-56.
16. Luc G, Bard JM, Arveiler D, et al. Lipoprotein(a) as a predictor of coronary heart disease: the PRIME study. Atherosclerosis 2002;163:377-84.
17. Cantin B, Després JP, Lamarche B, et al. Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study). Am J Cardiol 2002;89:662-66.
18. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease: meta-analysis of prospective studies. Circulation 2000;102:1082-5.
19. Friedewald WT, Levy RI, Fredickison DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the use of preparative ultracentrifugue. Clin Chem 1972; 18:499-52.
20. Gupta R, Vasisht S, Bahl VK, et al. Correlation of lipoprotein(a) to angiographically defined coronary artery disease in Indians. Int J Cardiol 1996; 57:265-70.
21. Maranhão RC, Vinagre CG, Arie S, et al. Lipoprotein(a) in subjects with or without coronary artery disease: relation to clinical history and risk factors. Braz J Med Biol Res 1995;28:439-46.
22. Cantin B, Gagnon F, Moorjani S, et al. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol 1998; 31:519-25.
23. Cremer P, Nagel D, Labrot NB, et al. Lipoprotein(a) as a predictor of acute myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen risk incidence and prevalence study. Eur J Clin Invest 1994; 24: 444-53.
24. Schaefer EJ, Lamon-Fava S, Jenner JL, et al. Lipoprotein(a) levels and risk of coronary heart disease in men: the lipidic research clinics coronary primary prevention trial. JAMA 1994; 271: 999-1003.
25. Marcovina SM, Koschinsky ML. A critical evaluation of the role of Lp(a) in cardiovascular disease: can Lp(a) be useful in risk assessment? Semin Vasc Med 2002; 2:335-44.
26. Sposito AC, Mansur AP, Maranhão RC, et al. Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein(a) in type IIb dyslipidemic subjects. Braz J Med Biol Res 2001; 34: 177-82.
27. Mikhailidis DP, Ganotakis ES, Spyropoulos KA, et al. Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate of lifestyle advice. Int Angiol 1998; 17: 225-33.